New hope for cedar fever sufferers: drug eases severe allergy symptoms
NCT ID NCT03369704
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called omalizumab in 337 adults and teens with severe Japanese cedar pollen allergy (hay fever) that standard medicines couldn't control. Participants received either omalizumab or a placebo on top of their usual allergy treatments for 12 weeks. The goal was to see if the drug could better relieve nasal and eye symptoms during the worst part of the pollen season.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Chiba, Chiba, 262-0015, Japan
-
Novartis Investigative Site
Ichikawa, Chiba, 272-0143, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 2270082, Japan
-
Novartis Investigative Site
Matsudo, Chiba, 270-0034, Japan
-
Novartis Investigative Site
Matsudo, Chiba, 2710077, Japan
-
Novartis Investigative Site
Urayasu, Chiba, 279-0012, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 212-0027, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216 0006, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216-0002, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, Japan
-
Novartis Investigative Site
Koshigaya, Saitama, 343-0031, Japan
-
Novartis Investigative Site
Arakawa-ku, Tokyo, 116 0011, Japan
-
Novartis Investigative Site
Chiyoda-ku, Tokyo, 101-0063, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 103 0027, Japan
-
Novartis Investigative Site
Edogawa-ku, Tokyo, 132-0014, Japan
-
Novartis Investigative Site
Katsushika-ku, Tokyo, 125-0061, Japan
-
Novartis Investigative Site
Nakano-ku, Tokyo, 164-0012, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 158-0097, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 160-0008, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 160-0017, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan
-
Novartis Investigative Site
Toshima-Ku, Tokyo, 170-0005, Japan